A trial comparing rituximab with `watch and wait' for advanced follicular lymphoma

Cancer type:

Blood cancers
Low grade lymphoma
Non-Hodgkin lymphoma




Phase 3

This trial was comparing rituximab (Mabthera) with 'watch and wait' for people with follicular lymphoma who didn't have symptoms. This trial was supported by Cancer Research UK.

Follicular lymphoma is a common type of non Hodgkin lymphoma (NHL) and is generally classed as a low grade lymphoma. This means that the lymphoma usually grows quite slowly, over a number of years.

If you have low grade follicular lymphoma, you may not have treatment as soon as you are diagnosed. Your doctor may keep an eye on you. This is sometimes called ‘watchful waiting’ or ‘watch and wait’. You doctor may recommend you start chemotherapy if your lymphoma starts to grow more quickly, or if you feel less well.

Rituximab is a type of biological therapy called a monoclonal antibody. It is already used to treat some people with low grade lymphoma, alongside chemotherapy.

This trial was trying to find out if having immediate treatment with rituximab on its own could delay the time until you need to start other chemotherapy.

Summary of results

The trial recruited 463 people who had been diagnosed with follicular lymphoma but did not have any symptoms. It was a randomised trial, so the people taking part were put into 1 of 3 treatment groups by computer. Neither they, nor their doctors could choose which group they were in

  • People in group A had no treatment (watch and wait)
  • People in group B had rituximab once a week for 4 weeks
  • People in group C had rituximab once a week for 4 weeks, then once every 2 months for 2 years

When the trial had been running for 3 years, it stopped recruiting people into group B because other studies had shown that having rituximab for longer helped people more.

The trial team looked at how many people had still not started other treatment 3 years after joining the trial. They found this was

  • Just under half (48%) of the people in group A
  • 8 out of 10 people (80%) in group B
  • More than 9 out of 10 people (91%) in group C

The side effects of rituximab included a drop in the number of white blood cells, sometimes leading to infections, and 5 people had an allergic reaction to the drug.

The researchers presented these results at a conference in December 2010. At this time, the results did not show that rituximab helped the people in this trial to live longer, but it did delay the time until they needed to start other treatment. So the researchers suggest rituximab could become a treatment for people when they are first diagnosed with follicular lymphoma, even if they don’t have symptoms.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Kirit Ardeshna

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Lymphoma Association
National Institute for Health Research Cancer Research Network (NCRN)

Other information

This is Cancer Research UK trial number CRUKE/03/016.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 385

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page